A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

Inclusion Criteria

• •1. Participants voluntarily agree to participate in this study and sign an Institutional Review Board (IRB)-approved informed consent form (ICF) prior to performing any of the screening procedures.
• •Parkinson's Disease Related Criteria:
• •2. Diagnosis of Parkinson's disease (PD) with motor symptom improvement from levodopa, if applicable.
• •3. Less than 5 years from the initial PD diagnosis, at the time of ICF.
• •4. Early-stage PD, with mild symptoms based on standard clinical staging in OFF state.
• •5. Participants who are on immediate-release levodopa-carbidopa/benserazide.
• •Other Health Related Criteria
• •6. No active cancer, unless in remission for ≥10 years without ongoing treatment, except fully removed basal cell carcinoma.
• •7. Free of significant health issues that might interfere with study participation.
• •Other Criteria/Social Circumstances
• •8. Negative screening for illegal drugs (excluding cannabis), with willingness to abstain during the study and avoid cannabis or alcohol effects during visits.